Human Genome Sciences Inc., a GSK Company

Quick facts

Marketed products

• Belimumab plus Early Vaccination · Immunology
  Belimumab inhibits B-lymphocyte stimulator (BLyS) to reduce autoreactive B cells, combined with early vaccination to enhance immune response.
• Belimumab plus Late Vaccination

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Human Genome Sciences Inc., a GSK Company portfolio CI brief
• Human Genome Sciences Inc., a GSK Company pipeline updates RSS